Skip to main content
SpringerLink
Log in

α-Adrenoceptor Antagonists

  • Chapter
Pharmacology of Antihypertensive Therapeutics

Part of the book series: Handbook of Experimental Pharmacology ((HEP,volume 93 / 1))

Abstract

Ever since the development of α-adrenoceptor antagonistic drugs (α-blockers), attempts have been made to treat arterial hypertensive disease with such compounds. This approach would seem logical since α-adrenoceptor antagonists are vasodilators with a very strong action in the arteriolar vascular bed; in addition it should be realized that elevated total peripheral resistance is the most consistent hemodynamic change in established essential hypertension. Treatment with vasodilator drugs thus seems a rational route to lower blood pressure in hypertensive patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Amery A (ed) (1986) Treatment of hypertension with urapidil. Preclinical and clinical update. R Soc Med Serv 101: 1–186

    Google Scholar 

  • Amann FW, Bolli P, Kiowski W et al. (1981) Enhanced α-adrenoceptor-mediated vasoconstriction in essential hypertension. Hypertension 3 (Suppl I): 119–123

    Google Scholar 

  • Awan N, Hermanovich J, Vera Z et al. (1982) Cardiocirculatory actions of trimazosin and sodium nitroprusside in ischemic heart disease. Clin Pharmacol Ther 31: 290

    Article  PubMed  CAS  Google Scholar 

  • Bateman DN, Hobbs DC, Twomey TM et al. (1979) Prazosin, pharmacokinetics and concentration effect. Eur J Clin Pharmacol 16: 177–181

    Article  PubMed  CAS  Google Scholar 

  • Berthelsen S, Pettinger WA (1977) A functional basis for classification of α-adrenergic receptors. Life Sci 21: 595–606

    Article  PubMed  CAS  Google Scholar 

  • Brodde OE, Daul AE, O’Hara N, Bock KD (1984) Increased density and responsiveness of α- and p-adrenoceptors in circulating blood cells of essential hypertensive patients. J Hypertens 2 (Suppl 3): 111–113

    Google Scholar 

  • Brodde OE, Daul AE, O’Hara H, Khalifa AM (1985) Properties of α- and β-adrenoceptors in circulating blood cells of patients with essential hypertension. J Cardiovasc Pharmacol 7: S162–S167

    Article  PubMed  Google Scholar 

  • Brogden RN, Heel RC, Speight TM, Avery GS (1977) Prazosin: a review of its pharmacological properties and therapeutic efficacy in hypertension. Drugs 14: 163–197

    Article  PubMed  CAS  Google Scholar 

  • Buehler FR, Bolli P, Erne P, Kiowski W, Mueller FB, Hulth6n UL, Ji BH (1985) Adrenoceptors, calcium and vasoconstriction in normal and hypertensive humans. J Cardiovasc Pharmacol 7. S130–S136

    Article  CAS  Google Scholar 

  • Cambridge D, Davey MJ, Massingham R (1977) The pharmacology of antihypertensive drugs with special reference to vasodilators, α-adrenergic blocking agents and prazosin. Med J Aust (Suppl 2 ): 2

    CAS  Google Scholar 

  • Cambridge D, Davey MJ, Greengrass PM (1980) The pharmacology of antihypertensive drugs with special reference to vasodilators, α-adrenergic blocking agents and prazosin. Prog Pharmacol 3: 107

    CAS  Google Scholar 

  • Cavero I (1982) Effects of prazosin on reflex changes in heart rate evoked by vasopressor and vasodepressor stimuli in conscious rabbits. J Cardiovasc Pharmacol 4 (Suppl): S108

    Article  PubMed  Google Scholar 

  • Cavero I, Roach AG (1980) The pharmacology of prazosin, a novel antihypertensive agent. Life Sci 27: 1525–1533

    Article  PubMed  CAS  Google Scholar 

  • Constantine JW, Hess HJ (1981) The cardiovascula effects of trimazosin. Eur J Pharmacol 74: 227

    Article  PubMed  CAS  Google Scholar 

  • Constantine JW, McShane WK, Scriabine A, Hess HJ (1973) Analysis of the hypotensive action of prazosin. In: Onesti G, Kim KE, Moyer JH (eds) Hypertension: mechanisms and management. Grune and Stratton, New York, p 429

    Google Scholar 

  • Constantine JW, Weeks RA, McShane WK (1978) Prazosin and presynaptic α-receptors in the cardio-accelerator nerve of the dog. Eur J Pharmacol 50: 51

    Article  PubMed  CAS  Google Scholar 

  • Cubeddu LX, Zarate NA, Rosales CB, Zschaek W (1982) Prazosin and propranolol in preoperative management of phaeochromocytoma. Clin Pharmacol Ther 32: 156–160

    Article  PubMed  CAS  Google Scholar 

  • De Jonge A, Timmermans PBMWM, Van Zwieten PA (1981) Participation of cardiac presynaptic α2-adrenoceptors in the bradycardiac effects of Clonidine and analogues. Nauyn Schmiedebergs Arch Pharmacol 317: 8–12

    Article  Google Scholar 

  • Doxey JC, Smith CFC, Walker JM (1977) Selectivity of blocking agents for pre- and postsynaptic α-adrenoceptors. Br J Pharmacol 60: 91

    PubMed  CAS  Google Scholar 

  • Drayer JIM, Weber MA, De Young JL, Brewer DD (1983) Long term blood pressure monitoring in the evaluation of antihypertensive therapy. Arch Intern Med 143: 898–901

    Article  PubMed  CAS  Google Scholar 

  • Elliott HL, McLean K, Sumner DJ et al. (1981) Immediate cardiovascular responses to oral prazosin—effects on current β-blockers. Clin Pharmacol Ther 29: 303

    Article  PubMed  CAS  Google Scholar 

  • Elliott HL, Meredith PA, Sumner DJ et al. (1982) A pharmacodynamic and pharmacokinetic assessment of a new a-adrenoceptor antagonist, doxazosin (UK 33274) in normotensive subjects. Br J Clin Pharmacol 13: 699

    PubMed  CAS  Google Scholar 

  • Georgopoulos AJ, Valasidis A, Siourthas D (1978) Treatment of chronic heart failure with slow release phentolamine. Eur J Clin Pharmacol 13: 325

    Article  PubMed  CAS  Google Scholar 

  • Gould L, Becker WH, Macklin EE (1980) Effects of intravenous phentolamine on hemodynamics and restind pulmonary gas exchange in man. Angiology 31: 120

    Article  PubMed  CAS  Google Scholar 

  • Graham RM, Pettinger WA (1979) Prazosin. N Engl J Med 300: 232–236

    Article  CAS  Google Scholar 

  • Greengrass PM, Bremner R (1979) Binding characteristics of 3H-prazosin to rat brain α-adrenergic receptors. Eur J Pharmacol 55: 323

    Article  PubMed  CAS  Google Scholar 

  • Hamilton CA, Reid JL, Vincent J (1985) Pharmacokinetic and pharmacodynamic studies with two α-adrenoceptor antagonists, doxazosin and prazosin in the rabbit. Br J Pharmacol 86: 79–87

    PubMed  CAS  Google Scholar 

  • Hardey DW, Lokhandwala MF (1979) Influence of prazosin on cardiac reflex function. Eur J Pharmacol 57: 251

    Article  PubMed  CAS  Google Scholar 

  • Hess HJ (1974) Biochemistry and structure-activity studies with prazosin. In: Cotton DKW (ed) Prazosin—evaluation of a new antihypertensive agent. Excerpta Medica, Amsterdam, p 5

    Google Scholar 

  • Hornung R, Presek P, Glossman H (1979) Alpha-adrenoceptors in rat brain: direct identification with prazosin. Naunyn Schmiedebergs Arch. Pharmacol 308: 223

    Google Scholar 

  • Huchet AM, Velly J, Schmitt H (1981) Role of αr and α2-adrenoceptors in the modulation of the baroreflex vagal bradycardia. Eur J Pharmacol 71: 455–461

    Article  PubMed  CAS  Google Scholar 

  • Imhof PR, Carnier B, Brunner L, Keller G, Rohrer T (1976) Human Pharmacology of orally administered phentolamine. In: Taylor SH (ed) Phentolamine in heart failure and other cardiac disorders. Huber, Bern, pp 11–22

    Google Scholar 

  • Jie K, Van Brummelen P, Vermey P, Timmermans PBMWM, Van Zwieten PA (1984) Identification of vascular postsynaptic αr and α2-adrenoceptors in man. Circ Res 54: 447–452

    PubMed  CAS  Google Scholar 

  • Jie K, Van Brummelen P, Vermey P, Timmermans PBMWM, Van Zwieten PA (1986) ar and α2-Adrenoceptor mediated vasoconstriction in the forearm of normotensive and hypertensive subjects. J Cardiovasc Pharmacol 8: 190–196

    Google Scholar 

  • Jones CR, Hamilton CA, Whyte KF, Elliott HL, Reid JL (1985) Acute and chronic α-Adrenoceptor regulation of alpha(2)-adrenoceptor number and function in man. Clin Sci 68 (Suppl 10): 129S–132S

    PubMed  CAS  Google Scholar 

  • Kiowski W, Hulthen UL, Ritz R, Buehler FR (1983) Alpha-2-adrenoceptor mediated vasoconstriction in human arterial vessels. J Clin Pharmacol Ther 34: 565–569

    Article  CAS  Google Scholar 

  • Kobinger W (1978) Central a-adrenergic systems as targets for hypotensive drugs. Rev Physiol Biochem Pharmacol 81: 40–100

    Google Scholar 

  • Kobrin I, Gallo A, Kumar A, Pegram BL, Fröhlich ED (1984) Immediate hemodynamic changes produced by Urapidil in normotensive and spontaneously hypertensive rats. Clin Exp Hypertens A6: 685–697

    Article  CAS  Google Scholar 

  • Kondo K, Ohashi K, Ebiwara A (1982) Pharmacokinetics and pharmacological effects of terazosin, a new alpha-blocker. Jpn J Clin Pharmacol Ther 13: 137–138

    Article  Google Scholar 

  • Kyncl JJ (1986) The pharmacology of terazosin. Am J Med 80 (Suppl 5B): 12–19

    Article  PubMed  CAS  Google Scholar 

  • Langer SZ (1981) Presynaptic regulation of the release of catecholamines. Pharmacol Rev 32: 337–362

    Google Scholar 

  • Langer SZ, Massingham R, Shepperson NB (1980) Presence of postsynaptic α2-adrenoceptors of predominantly extrasynaptic location in the vascular smooth muslce of the dog hind limb. Clin Sci 59 (Suppl 6): 225S–228S

    PubMed  CAS  Google Scholar 

  • Lefövre-Borg F, Roach AG, Gomeni R, Cavero I (1979) Mechanism of antihypertensive activity of orally administered prazosin in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1: 31

    Article  Google Scholar 

  • Lund-Johansen P (1974) Hemodynamic changes at rest and during exercise in long-term prazosin therapy of essential hypertension. In: Cotton DKW (ed) Prazosin—evaluation of a new antihypertensive agent. Excerpta Medica, Amsterdam, p 43

    Google Scholar 

  • Lui HK, Awan NA, Needham K, Mason DT (1985) Comparative evaluation of the new oral systemic vasodilator terazosin and nitroprusside in severe chronic heart failure. Clin Res 33: 207A

    Google Scholar 

  • Marshall AJ, Kettle MA, Barritt DW (1980) Evaluation of indoramin added to Oxprenolol and bendrofluazide as a third agent in severe hypertension. Br J Clin Pharmacol 10: 217

    PubMed  CAS  Google Scholar 

  • Messerli FH, Kobrin I, Amodeo C, Ventura HO, Fröhlich ED (1986) Immediate cardiovascular effects of Urapidil in essential hypertension. In: Amery A (ed) Treatment of hypertension with Urapidil. Roy Soc Med Serv 101: 87–91

    Google Scholar 

  • Miach PJ, Dausse JP, Cardot A, Meyer P (1980) 3H-Prazosin binds specifically to ar adrenoceptors in rat brain. Naunyn Schmiedebergs Arch Pharmacol 312: 23

    Google Scholar 

  • Moser M (ed) (1986) Advances in the management of hypertension: focus on terazosin, a new alpha-l-adrenergic antagonist. Am J Med 80 (5B): 1–105

    Google Scholar 

  • Motulsky HJ, O’Connor DT, Insel PA (1983) Platelet a2-adrenergic receptors in treated and untreated essential hypertension. Clin Sei 64: 265–272

    CAS  Google Scholar 

  • Perry RS (1985) Trimazosin. Drugs Today 21: 243–252

    Google Scholar 

  • Persson B, Yao T, Thoren P (1981) Correlation between decreased heart rate and central inhibition of sympathetic discharges after prazosin administration in the spontaneously hypertensive rat. Clin Exp Hypertens 3: 245–250

    Article  PubMed  CAS  Google Scholar 

  • Philipp T, Distler A, Cordes U (1978) Sympathetic nervous system and blood pressure control in essential hypertension. Lancet 2: 959–963

    Article  PubMed  CAS  Google Scholar 

  • Preston RA, O’Connor DT, Stone RA (1979) Prazosin and renal hemodynamics: arteriolar vasodilatation during therapy of essential hypertension in man. J Cardiovasc Pharmacol 1: 277

    Article  PubMed  CAS  Google Scholar 

  • Ramage AG (1982) Why do aradrenoceptor antagonists fail to cause reflex tachycardia? Br J Pharmacol 77 (Suppl): 323 P

    Google Scholar 

  • Reid JL, Meredith PA, Elliott H (1983) Pharmacokinetics and pharmacodynamic of trimazosin in man. Am Heart J 106: 1222–1228

    Article  PubMed  CAS  Google Scholar 

  • Roach AG, Gomeni R, Mitchard M et al. (1978) The blood pressure lowering effects of intravenous versus intracerebroventricular prazosin in anesthetized cats. Eur J Pharmacol 49: 271–274

    Article  PubMed  CAS  Google Scholar 

  • Robinson BF (1981) Drugs acting directly on vascular smooth muscle: circulatory and secondary effects. Br J Pharmacol 12: 5S

    Google Scholar 

  • Roesler JM, McCafferty JP, De Marinis RM, Matthews WD, Hieble JP (1986) Characterization of the antihypertensive activity of SK & F 86466, a selective α2-antagonist in the rat. J Pharmacol Exp Ther 236: 1–7

    PubMed  CAS  Google Scholar 

  • Saeed M, Sommer O, Holtz J, Bassenge E (1982) α-Adrenoceptor blockade by phentolamine causes β-adrenergic vasodilatation by increased catecholamine release due to presynaptic a-blockade. J Cardiovasc Pharmacol 4: 44–48

    Google Scholar 

  • Sands H, Jorgensen R (1979) Effects of prazosin on cyclic nucleotide content and blood pressure of the spontaneously hypertensive rat. Biochem Pharmacol 28: 685–687

    Article  PubMed  CAS  Google Scholar 

  • Sasso EH, O’Conner DT (1982) Prazosin depression of baroreflex function in hypertensive man. Eur J Clin Pharmacol 22: 7–9

    Article  PubMed  CAS  Google Scholar 

  • Schmitt H (1971) Action des a-sympathomimetiques sur les structures nerveuses. Actual Pharmacol 24: 93–113

    CAS  Google Scholar 

  • Schoetensack W, Bruckschen EG, Zech K (1983) Urapidil. In: Scriabine W (ed) New drugs annual: Cardiovascular drugs. Raven, New York, pp 19–48

    Google Scholar 

  • Singleton W, Saxton CAPD, Hernandez R, Ferrer RS, Pritchard BNC (1980) Alpha blocking effect of prazosin, trimazosin and UK-33,274 in man. In: Turner P (ed) World conference on clin pharmac ther Abs. MacMillan, London

    Google Scholar 

  • Singleton W, Sexton CAPD, Hernandez J, Prichard BN (1982). Postjunctional selectivity of α-blockade with prazosin, trimazosin and UK-33,274 in man. J Cardiovasc Pharmacol 4: S145–S155

    Article  PubMed  Google Scholar 

  • Sonders RC (1986) The pharmacokinetics of terazosin. Am J Med 80: (Suppl 5B): 77–81

    Article  Google Scholar 

  • Stanaszek WF, Kellerman D, Brogden RN (1983) Romankiewicz. Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure. Drugs 25: 339–384

    Google Scholar 

  • Starke K (1981) α-Adrenoceptor subclassification. Rev Physiol Biochem Pharmacol 88:199–236

    Google Scholar 

  • Stokes GS, Frost GW, Graham RM, MacCarthy EP (1979) Indoramin and prazosin as adjuncts to beta-adrenoceptor blockade in hypertension. Clin Pharmacol Ther 25: 783–785

    PubMed  CAS  Google Scholar 

  • Taylor CR, Leader JP, Singleton MB, Munster EW, Falkner FC (1983) Profile of trimazosin: an effective and safe antihypertensive agent. Am Heart J 106: 1269–1285

    Article  PubMed  CAS  Google Scholar 

  • Taylor LA, Twomey TM, Schuch von Wintenau M (1977) The metabolic fate of prazosin. Xenobiotica 7: 357–364

    Google Scholar 

  • Timmermans PBMWM, Van Zwieten PA (1981) The postsynaptic α2-adrenoceptor. J Auton Pharmacol 1: 171–183

    Article  PubMed  CAS  Google Scholar 

  • Timmermans PBMWM, Van Zwieten PA (1982) α2-Adrenoceptors: classification, localisation, mechanisms and targets for drugs. J Med Chem 25: 1389–1401

    Google Scholar 

  • Timmermans PBMWM, Lam E, Van Zwieten PA (1979) The interaction between prazosin and Clonidine at α-adrenoceptors in rats and cats. Eur J Pharmacol 49: 271–276

    Google Scholar 

  • Timmermans PBMWM, Kwa HY, Karamat Ali F, Van Zwieten PA (1980) Prazosin and its analogues UK-18,596 and UK-33,274: a comparative study on cardiovascular effects and α-adrenoceptor blocking activities. Arch Int Pharmacodyn 245: 218

    Google Scholar 

  • Titmarsch S, Monk JP (1987) Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension. Drugs 33: 461–477

    Google Scholar 

  • U’Prichard DC, Charness ME, Robertson D, Snyder S (1978) Prazosin: differential affinities for two populations of α-adrenergic receptor binding sites. Eur J Pharmacol 50: 87

    Article  PubMed  Google Scholar 

  • Van Brummelen P, Jie K, Timmermanns PBMWM, Van Zwieten PA (1985) Postjunctional α-adrenoceptors and the regulation of arteriolar tone in humans. J Cardiovase Pharmacol 7: S149–S152

    Article  Google Scholar 

  • Van Zwieten PA (1975) Antihypertensive drugs with a central action. Prog Pharmacol 1: 1–63

    Google Scholar 

  • Van Zwieten PA (1984) Role of α-adrenoceptors in hypertension and antihypertensive drug treatment. Am J Med 77: 17–25

    PubMed  Google Scholar 

  • Van Zwieten PA, Timmermans PBMWM (1983) Cardiovascular α2-adrenoceptors. J Mol Cell Cardiol 15: 717–733

    Article  PubMed  Google Scholar 

  • Van Zwieten PA, Timmermans PBMWM (1984) Pharmacological basis for the hypotena-Adrenoceptorsive activity and side-effects of a-methyl-DOPA, Clonidine and guanfacine. Hypertension (Suppl 6 ): 28–33

    Google Scholar 

  • Van Zwieten PA, De Jonge A, Wilffert B, Timmermans PBMWM, Beckeringh JJ, Thoolen MJMC (1985) Cardiovascular effects and interaction with adrenoceptors of Urapidil. Arch Int Pharmacodyn 276: 180–201

    PubMed  Google Scholar 

  • Vincent J, Hamilton CA, Sumner DJ, Reid JL (1983a) A comparison of the hypotensive activity and in vitro and in vivo α-adrenoceptor antagonist properties of prazosin, trimazosin and doxazosin in the rabbit. Br J Pharmacol 79 (Suppl): 388 P

    Google Scholar 

  • Vincent J, Elliott HL, Meredith PA, Reid JL (1983b) Doxazosin, an aradrenoceptor antagonist. Pharmacokinetics and concentration effect relationships in man. Br J Clin Pharmacol 15: 719–725

    PubMed  CAS  Google Scholar 

  • Wilffert B, Timmermans PBMWM, Van Zwieten PA (1982) Extrasynaptic location of α2-and non-innervated β2-adrenoceptors in the vascular system of the pithed normotensive rat. J Pharmacol Exp. Ther 221: 762–768

    PubMed  CAS  Google Scholar 

  • Wood AJ, Bolli P, Simpson FO (1976) Prazosin in normal subjects: plasma levels, blood pressure and heart rate. Br J Pharmacol 3: 199–202

    CAS  Google Scholar 

  • Zech K, Steinijans VW, Radtke HW (1986) Pharmacokinetics of Urapidil in normal subjects. In: Amery A (ed) Treatment of hypertension with Urapidil. Roy Soc Med Serv 101: 29–38

    Google Scholar 

Download references

Authors
  1. P. A. van Zwieten
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. German Institute for High Blood Pressure Research and Department of Pharmacology, University of Heidelberg, Im Neuenheimer Feld 366, D-6900, Heidelberg, Germany

    Detlev Ganten M.D, Ph.D.

  2. Medical College of Ohio, CS10008, 300 Arlington Avenue, Toledo, OH, 43699, USA

    Patrick J. Mulrow M.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

van Zwieten, P.A. (1990). α-Adrenoceptor Antagonists. In: Ganten, D., Mulrow, P.J. (eds) Pharmacology of Antihypertensive Therapeutics. Handbook of Experimental Pharmacology, vol 93 / 1. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74209-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-74209-5_4

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-74211-8

  • Online ISBN: 978-3-642-74209-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation